BR112022009856A2 - Compostos de 1,8-naftiridin-2-ona para o tratamento de doença autoimune - Google Patents

Compostos de 1,8-naftiridin-2-ona para o tratamento de doença autoimune

Info

Publication number
BR112022009856A2
BR112022009856A2 BR112022009856A BR112022009856A BR112022009856A2 BR 112022009856 A2 BR112022009856 A2 BR 112022009856A2 BR 112022009856 A BR112022009856 A BR 112022009856A BR 112022009856 A BR112022009856 A BR 112022009856A BR 112022009856 A2 BR112022009856 A2 BR 112022009856A2
Authority
BR
Brazil
Prior art keywords
compounds
naftiridin
treatment
autoimmune disease
ona
Prior art date
Application number
BR112022009856A
Other languages
English (en)
Inventor
Shen Hong
Wang Xiaoqing
Xu Hongtao
Zhang Zhisen
Zhu Wei
zou Ge
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112022009856A2 publication Critical patent/BR112022009856A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

COMPOSTOS DE 1,8-NAFTIRIDIN-2-ONA PARA O TRATAMENTO DE DOENÇA AUTOIMUNE. A presente invenção refere-se a compostos de fórmula (I), em que R¹ a R³, m e n são conforme descritos neste documento, e o sal, enantiômero ou diastereômero farmaceuticamente aceitável do mesmo, e composições incluindo os compostos e métodos para usar os compostos
BR112022009856A 2019-11-26 2020-11-24 Compostos de 1,8-naftiridin-2-ona para o tratamento de doença autoimune BR112022009856A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019120996 2019-11-26
PCT/EP2020/083113 WO2021105072A1 (en) 2019-11-26 2020-11-24 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
BR112022009856A2 true BR112022009856A2 (pt) 2022-08-02

Family

ID=73598065

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009856A BR112022009856A2 (pt) 2019-11-26 2020-11-24 Compostos de 1,8-naftiridin-2-ona para o tratamento de doença autoimune

Country Status (16)

Country Link
US (1) US20230041743A1 (pt)
EP (1) EP4065586A1 (pt)
JP (1) JP2023503165A (pt)
KR (1) KR20220106126A (pt)
CN (1) CN114728987A (pt)
AR (1) AR120540A1 (pt)
AU (1) AU2020393367A1 (pt)
BR (1) BR112022009856A2 (pt)
CA (1) CA3156457A1 (pt)
CO (1) CO2022006942A2 (pt)
CR (1) CR20220231A (pt)
IL (1) IL291640A (pt)
MX (1) MX2022005912A (pt)
PE (1) PE20221026A1 (pt)
TW (1) TW202134238A (pt)
WO (1) WO2021105072A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4273773A (en) * 1979-09-24 1981-06-16 American Home Products Corporation Antihypertensive tricyclic isoindole derivatives
ES2755130T3 (es) * 2013-02-08 2020-04-21 Nissan Chemical Corp Compuesto de pirrolopiridina tricíclico, e inhibidor de JAK
MY196319A (en) * 2015-12-17 2023-03-24 Merck Patent Gmbh Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
EP3601282B1 (en) * 2017-03-30 2021-07-21 F. Hoffmann-La Roche AG Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection
CA3059939A1 (en) * 2017-04-21 2018-10-25 Kyn Therapeutics Indole ahr inhibitors and uses thereof

Also Published As

Publication number Publication date
EP4065586A1 (en) 2022-10-05
WO2021105072A1 (en) 2021-06-03
CA3156457A1 (en) 2021-06-03
IL291640A (en) 2022-05-01
CN114728987A (zh) 2022-07-08
CO2022006942A2 (es) 2022-06-10
CR20220231A (es) 2022-06-27
TW202134238A (zh) 2021-09-16
AU2020393367A1 (en) 2022-04-14
US20230041743A1 (en) 2023-02-09
PE20221026A1 (es) 2022-06-16
JP2023503165A (ja) 2023-01-26
MX2022005912A (es) 2022-06-24
KR20220106126A (ko) 2022-07-28
AR120540A1 (es) 2022-02-23

Similar Documents

Publication Publication Date Title
CL2019002204A1 (es) Compuestos inhibidores del vih.
EA201892480A1 (ru) Соединения, модулирующие fxr (nr1h4)
EA201791002A1 (ru) Новые соединения, модулирующие fxr (nr1h4)
BR112017003975A2 (pt) composição de conjugado de ligante e fármaco, e, composto ligador de fármaco.
EA201892482A1 (ru) Соединения, модулирующие fxr (nr1h4)
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
EA201692418A1 (ru) Замещенные индазольные соединения в качестве irak4 ингибиторов
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
EA201890338A1 (ru) Оксадиазольные производные, пригодные в качестве ингибиторов hdac
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
BR112021007788A8 (pt) Composto inibidor de jak 2-azabiciclo hexano
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
EA201990833A1 (ru) Соединение пиридина
BR112022006242A2 (pt) Compostos aromáticos de arilmetileno como bloqueadores de canal do agitador de potássio kv1,3
EA201691071A1 (ru) Фенилтриазолопиридиновые соединения
BR112016024936A2 (pt) moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
BR112019025230A2 (pt) Anéis 5-5 fundidos como inibidores de c5a
TN2018000372A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions.
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
BR112021006319A2 (pt) compostos de indolinona para uso como inibidores de map4k1
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
NZ746906A (en) Oxaborole esters and uses thereof
BR112022006202A2 (pt) Compostos heterocíclicos de arila como bloqueadores de canal do agitador de potássio kv1,3

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]